

Received: 2001.12.15
Accepted: 2001.12.21
Published: 2002.01.09

Authors' Contribution:

- A** Study Design
- B** Data Collection
- C** Statistical Analysis
- D** Data Interpretation
- E** Manuscript Preparation
- F** Literature Search
- G** Funds Collection

Tonal nitric oxide and health – a free radical and a scavenger of free radicals

Danielle Benz, Patrick Cadet, Kirk Mantione, Wei Zhu, George B. Stefano

Neuroscience Research Institute, State University of New York at Old Westbury, Old Westbury, New York, USA

Source of support: This work was in part supported by NIDA 09010 and the Cell Dynamics, Corp.

Summary:

Basal/tonal nitric oxide (NO) production helps maintain particular microenvironments, i.e., vascular. Besides NO's function in controlling the activation state of various tissues such as immune cells, its presence appears to modulate other free radical levels, i.e., H₂O₂, in these same tissues and indeed these processes may be one and the same. Thus, by being a free radical, along with the ability to scavenge other free radicals, NO is placed in a pivotal regulatory position. We surmise that in the absence of adequate NO release other free radicals may go 'unchecked' and, therefore, initiate tissue damage. Furthermore, under these circumstances, proinflammatory events will occur due to heightened cell sensitivity and a diminished control of NF-κB. In an excess situation, and one without an appropriate circumstance, i.e., microbial action, NO may become the harmful agent. Hence, balancing basal NO production in body compartments may represent a fundamental process in maintaining general, long-term health.

key words:

nitric oxide • free radical • NF-κB • basal nitric oxide • tonal nitric oxide • antioxidant • immunocytes • vascular endothelial cells

Full-text PDF:

http://www.MedSciMonit.com/pub/vol_8/no_1/2403.pdf

File size:

61 kB

Word count:

1655

Tables:

–

Figures:

–

References:

69

Author's address:

George B. Stefano, Neuroscience Research Institute, State University of New York at Old Westbury, Old Westbury, New York 11568, USA, e-mail: gstefano@optonline.net

NITRIC OXIDE

Nitric oxide (NO) signaling occurs in diverse systems including the immune, cardiovascular and nervous [1-6]. It also occurs in evolutionarily diverse organisms [7,8]. NO is produced from L-arginine by the enzyme NO synthase (NOS) [4,9], which occurs in three forms: endothelial (e), neuronal (n) and inducible (i) NOS.

NO derived from e- or n- (constitutively [c] expressed forms) cNOS may occur in two functional forms: the first is always present at low 'tonal' or 'basal' levels which can be increased slightly for a short time in response to various biological signals [5] such as acetylcholine (ACH). This brief enhanced release of cNOS derived NO can have profound physiological actions that are evident long after NO levels have returned to the basal level of production [10]. In this regard, immune and vascular endothelial cells can be down regulated by NO, see [7]. We have hypothesized that certain classes of cells are always activated and thus can respond to immediate microenvironmental changes [7]. We further speculate that basal or tonal NO levels may provide a major pathway to dampen these cells sensitivity to microenvironmental 'noise' that would otherwise nonspecifically and inappropriately lead to increased activation [7]. In this regard, NO may modulate the threshold required for activation of these cells [7] and the magnitude of the subsequent response [11]. Diminished NO levels would then represent a disinhibition process that results in an overcoming of the inhibitory influence by changing the level of NO production and the corresponding levels of excitatory signals required for cellular activation (see [7]).

NO AND NF-KB

As an example of tonal NO's significance, the transcription factor NF-kB plays a pivotal role in regulation of gene expression induced by inflammatory mediators such as cytokines and adhesion molecules [12]. NO has been associated with NF-kB inactivation [13-17]. Our previous reports document the effect of NO on NF-kB [7,18-20]. NF-kB mediated transcriptional activation of many proinflammatory signal molecules/genes is inhibited by NO in a variety of cells including monocytes [7,18-23]. Thus, NO, aside from its cGMP influences, profoundly impacts DNA events leading to proinflammatory events.

NO AS AN ANTIOXIDANT FREE RADICAL

The intensity and diversity of current research regarding NO demonstrate the complexity of the interactions of this simple molecule. NO, a free radical, has actually been shown to be a beneficial antioxidant against reactive oxygen species (ROS), such as H_2O_2 and O_2^- , [24,25]. When L-arginine, a precursor of NO, was administered to rats in which experimental allergic encephalitis (EAE) was induced, increased levels of NO were shown to be correlated to a decrease in superoxide and hydrogen peroxide levels, demonstrating a role as a protective molecule [26]. There is also evidence of a role

in the production of ROS. Varying rates of endogenous NO production resulted in a reciprocal correlation of released H_2O_2 in rat liver mitochondria. This seems to be due to a regulation of O_2 consumption at the level of the cytochrome oxidase [27]. It has been found that the antioxidant properties of NO can be greatly increased by the activation of specific pathways leading to increased endogenous antioxidant production or down regulated pro-inflammatory responses [28].

Much research has also been done to examine NO's role in decreasing lipid peroxidation [24,29-31], but this process appears to be determined by the relative concentration of NO as compared to the reactive oxidant species. When it is in excess of the ROS, then lipid oxidation is decreased; but when NO levels drop below that of the ROS, lipid oxidation reactions propagate [32]. Nitric oxide has also been demonstrated to protect cells from tert-butyl hydroperoxide (tBOOH), a compound of lipid peroxidation. The generation of tBOOH-derived free radicals and tBOOH-induced cytotoxicity were both attenuated by endogenously produced or exogenously added NO [33-35]. In human erythroleukemia cells, t-BuOOH-induced oxoferryl and t-BuO alkoxyl radicals were chemically reduced by NO [34].

From the earlier discussion it becomes clear that the basal level of NO, derived from cNOS, may serve as the key modulator regulating a complex cascading process associated with maintaining cell health [7,36]. It becomes important to determine how a particular microenvironment may alter basal NO levels because, in turn, we learn how NO functions, varied by circumstance. NO has the potential to interact with oxygen, metals and other free radicals [37]. NO can also form peroxynitrite ($ONOO^-$) and dinitrogen trioxide (N_2O_3), following an interaction with the superoxide radical (O_2^-) and oxygen, respectively [38]. In this regard, NO's direct effect is felt when its level is low and of short duration, such as that occurring under physiological conditions, including the right pH [38]. For example, NO interaction with the heme proteins represents the activation of soluble guanylyl cyclase (sGC) and/or cyclooxygenase (COX) [39-41]. This last interaction is important in the regulation of a proinflammatory process [41]. At low concentrations (e.g., when it is scavenged), NO modulates the redox form of COX, converting the ferrous iron to the ferric active form, acting also as a scavenger of superoxide [38]. In addition, NO has the ability to inhibit lipoxigenase, as noted earlier [42]. It can reversibly inhibit the heme moiety of cytochrome P-450, preventing the binding of oxygen to the catalytic sites [43,44].

Interestingly, at low NO levels, H_2O_2 can be consumed to yield HNO_2 [38,45], suggesting that H_2O_2 might serve to control NO levels [38]. Indeed, the activation of monocytes, with interferon γ for 24hr, results in the appearance of activated ameoboid monocytes as opposed to inactive cells despite the production of high levels of NO. Cell activation is abrogated in the presence of catalase or superoxide dismutase, suggesting that H_2O_2

inhibition of NO suppression represents an important regulator of cellular activation [46]. Thus, in the absence of H_2O_2 , NO activity may be unregulated whereas in the absence of NO, H_2O_2 may generate tissue damage and disruption in energy metabolism as evident in Alzheimer's Disease [7,36]. In any case, the basal/tonal level of NO may represent a specific signal to maintaining 'cell' health.

Mitochondria represent a NO target due to the fact that NO is an inhibitor of cytochrome oxidase of the electron transport process [47-52], which suggests a NO role in modulating oxygen utilization [47]. The inhibition of cNOS-derived NO increases oxygen consumption in many animal species [53-57]. This last fact is critical to our NO hypothesis concerning alterations in basal NO levels since its regulatory process may be stopped (see earlier discussion). Furthermore, a NOS isoform, mtNOS, is present in mitochondria [48,58], suggesting an important modulatory function as well.

Heme proteins (e.g. hemoglobin, cytochromes, etc.) reacting with H_2O_2 results in ferryl cation ($Fe^{4+}+O$), a toxic substance [59]. However, once in contact with NO, this compound is reduced ($Fe^{3+}+NO_2^-$) [38], demonstrating again a NO antioxidant action. NO also has the potential to diminish the formation of OH^\bullet , again, demonstrating an antioxidant action [60]. This scavenging property gives NO a major intracellular and extracellular action against oxidative stress [38,61-67]. Here, we note that in the absence of NO, these reactive chemical species may cause tissue damage associated with a pathological progression.

In summary, it would appear that basal/tonal NO production helps maintain particular microenvironments, i.e., vascular, see [7,36,68]. Besides NO's function in controlling the activation state of various tissues, such as immune cells, its presence may also control free radical levels in these same tissues and indeed these processes may be one. Hence, by being a free radical, along with the ability to scavenge other free radicals, NO is placed in a pivotal regulatory position. We surmise that in the absence of adequate NO release, other free radicals may go 'unchecked' and, therefore, initiate tissue damage, see [36,68]. Furthermore, under these circumstances, proinflammatory events will occur due to heightened cell sensitivity and a diminished control of NF-kB. In an excess situation and one without an appropriate circumstance, i.e., antimicrobial action, NO, by itself, may become the harmful agent (see above). Thus, balancing and maintaining basal NO production, exerting a tonal effect, in microenvironments may represent a fundamental process in maintaining general health over the long term.

REFERENCES:

- Faraci FM, Heistad DD: Regulation of the cerebral circulation: role of endothelium and potassium channels. *Phys Rev*, 1998; 78: 53-97
- Kinoshita H, Tsutsui M, Milstien S, Katusic ZS: Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone. *Prog Neurobiol*, 1997; 52: 295-302
- Cooke JP, Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. *Ann Rev Med*, 1997; 48: 489-509
- Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacological Reviews*, 1991; 43: 109-42
- Moncada S, Palmer RM, Higgs EA: The discovery of nitric oxide as the endogenous nitrovasodilator. *Hypertension*, 1988; 12: 365-72
- Stefano GB, Scharrer B, Smith EM et al: Opioid and opiate immunoregulatory processes. *Crit Rev in Immunol*, 1996; 16: 109-44
- Stefano GB, Goumon Y, Bilfinger TV et al: Basal nitric oxide limits immune, nervous and cardiovascular excitation: Human endothelia express a mu opiate receptor. *Progress in Neurobiology*, 2000; 60: 531-44
- Stefano GB, Magazine HI: Nitric oxide autoregulation and its significance. *Modern Aspects of Immunobiology*, 2001; 1: 182-6
- Moncada S, Higgs A: The L-arginine-nitric oxide pathway. *New Eng J Med*, 1993; 329: 2002-12
- Magazine HI, Liu Y, Bilfinger TV et al: Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. *J Immunol*, 1996; 156: 4845-50
- Magazine HI, Chang J, Goumon Y, Stefano GB: Rebound from nitric oxide inhibition triggers enhanced monocyte activation and chemotaxis. *J Immunol*, 2000; 165: 102-7
- Blackwell TS, Blackwell TR, Holden EP et al: In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. *J Immunol*, 1996; 157: 1630-7
- Colasanti M, Persichini T, Menegazzi M et al: Induction of nitric oxide synthase mRNA expression. Suppression by exogenous nitric oxide. *Journal of Biological Chemistry*, 1995; 270: 26731-3
- Park SK, Lin HL, Murphy S: Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappa B binding to DNA. *Biochem J*, 1997; 322: 609-13
- Taylor BS, Kim YM, Wang Q et al: Nitric oxide down-regulates hepatocyte-inducible nitric oxide synthase gene expression. *Archives of Surgery*, 1997; 132: 1177-83
- Togashi H, Sasaki M, Frohman E et al: Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. *Proceedings of the National Academy of Sciences of the United States of America*, 1997; 94: 2676-80
- Katsuyama K, Shichiri M, Marumo F, Hirata Y: NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of Ikb-alpha. *Arteriosclerosis, Thrombosis & Vascular Biology*, 1998; 18: 1796-802
- Stefano GB: Autoimmunovascular regulation: morphine and anandamide stimulated nitric oxide release. *Journal of Neuroimmunology*, 1998; 83: 70-6
- Welters I, Fimiani C, Bilfinger TV, Stefano GB: NF-kB, nitric oxide and opiate signaling. *Medical Hypotheses*, 1999; 54: 263-8
- Welters ID, Menziesbach A, Goumon Y et al: Morphine inhibits NF-kB nuclear binding in human neutrophils and monocytes by a nitric oxide dependent mechanism. *Anesthesiol*, 2000; 92: 1677-84
- Peng HB, Libby P, Liao JK: Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. *J Biol Chem*, 1995; 270: 14214-9
- Peng HB, Spiecker M, Liao JK: Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. *Journal of Immunology*, 1998; 161: 1970-6
- Stefano GB, Salzet M, Magazine HI, Bilfinger TV: Antagonist of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. *J Cardiovasc Pharmacol*, 1998; 31: 813-20
- Wink DA, Miranda KM, Espey MG et al: Mechanisms of the antioxidant effects of nitric oxide. *Antioxidants & Redox Signaling*, 2001; 3: 203-13
- Svegliati-Baroni G, Saccomanno S, van Goor H et al: Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. *Liver*, 2001; 21: 1-12
- Scott GS, Bolton C: L-arginine modifies free radical production and the development of experimental allergic encephalomyelitis. *Inflammation Research*, 2000; 49: 720-6

27. Sarkela TM, Berthiaume J, Elfering S et al: The modulation of oxygen radical production by nitric oxide in mitochondria. *Journal of Biological Chemistry*, 2001; 276: 6945-9
28. Patel RP, Levenon A, Crawford JH, Darley-Usmar VM: Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. *Cardiovascular Research*, 2000; 47: 465-74
29. Korytowski W, Zareba M, Girotti AW: Inhibition of free radical-mediated cholesterol peroxidation by diazeniumdiolate-derived nitric oxide: effect of release rate on mechanism of action in a membrane system. *Chemical Research in Toxicology*, 2000; 13: 1265-74
30. Gutteridge JM, Halliwell B: Free radicals and antioxidants in the year 2000. A historical look to the future. *Annals of the New York Academy of Sciences*, 2000; 899: 136-47
31. Zhu W, Fung PC: The roles played by crucial free radicals like lipid free radicals, nitric oxide, and enzymes NOS and NADPH in CCl₄-induced acute liver injury of mice. *Free Radical Biology & Medicine*, 2000; 29: 870-80
32. Bloodworth A, O'Donnell VB, Freeman BA: Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. *Arteriosclerosis, Thrombosis & Vascular Biology*, 2000; 20: 1707-15
33. Chamulitrat W: EPR studies of nitric oxide interactions of alkoxyl and peroxy radicals in in vitro and ex vivo model systems. *Antioxidants & Redox Signaling*, 2001; 3: 177-87
34. Yalowich JC, Gorbunov NV, Kozlov AV et al: Mechanisms of nitric oxide protection against tert-butyl hydroperoxide-induced cytotoxicity in iNOS-transduced human erythroleukemia cells. *Biochemistry*, 1999; 38: 10691-8
35. Chamulitrat W: Nitric oxide inhibited peroxy and alkoxyl radical formation with concomitant protection against oxidant injury in intestinal epithelial cells. *Archives of Biochemistry & Biophysics*, 1998; 355: 206-14
36. de la Torre JC, Stefano GB: Evidence that Alzheimer's disease is a microvascular disorder: The role of constitutive nitric oxide. *Brain Res Rev*, 2000; 34: 119-36
37. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *American Journal of Physiology*, 1996; 271: C1424-C1437
38. Wink DA, Mitchell JB: Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. *Free Radical Biology & Medicine*, 1998; 25: 434-56
39. Murad F: Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone?. *Recent Progress in Hormone Research*, 1998; 53: 43-59
40. Denninger JW, Marletta MA: Guanylate cyclase and the NO/cGMP signaling pathway. *Biochimica et Biophysica Acta*, 1999; 1411: 334-50
41. Salvemini D: Regulation of cyclooxygenase enzymes by nitric oxide. *Cellular & Molecular Life Sciences*, 1997; 53: 576-82
42. Grisham MB, Granger DN, Lefer DJ: Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. *Free Radical Biology & Medicine*, 1998; 25: 404-33
43. Veihelmann A, Brill T, Blobner M et al: Inhibition of nitric oxide synthesis improves detoxication in inflammatory liver dysfunction in vivo. *American Journal of Physiology*, 1997; 273: G530-G536
44. Takemura S, Minamiyama Y, Imaoka S et al: Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. *Journal of Hepatology*, 1999; 30: 1035-44
45. Brown GC: Reversible binding and inhibition of catalase by nitric oxide. *European Journal of Biochemistry*, 1995; 232: 188-91
46. Srivastava KD, Magazine HI: Thrombin receptor activation inhibits monocyte spreading by induction of ET(B) receptor-coupled nitric oxide release. *J Immunol*, 1998; 161: 5039-44
47. Brown GC, Cooper CE: Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. *FEBS Letters*, 1994; 356: 295-8
48. Brown GC: Nitric oxide and mitochondrial respiration. *Biochimica et Biophysica Acta*, 1999; 1411: 351-69
49. Cleeter MW, Cooper JM, Darley-Usmar VM et al: Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. *FEBS Letters*, 1994; 345: 50-4
50. Schweizer M, Richter C: Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. *Biochemical & Biophysical Research Communications*, 1994; 204: 169-75
51. Takehara Y, Kanno T, Yoshioka T et al: Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. *Archives of Biochemistry & Biophysics*, 1995; 323: 27-32
52. Nishikawa M, Sato EF, Kuroki T, Inoue M: Role of glutathione and nitric oxide in the energy metabolism of rat liver mitochondria. *FEBS Letters*, 1997; 415: 341-5
53. Shen W, Hintze TH, Wolin MS: Nitric oxide. An important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. *Circulation*, 1995; 92: 3505-12
54. Shen W, Xu X, Ochoa M et al: Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. *Circulation Research*, 1994; 75: 1086-95
55. Laycock SK, Vogel T, Forfia PR et al: Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. *Circulation Research*, 1998; 82: 1263-71
56. King CE, Melinshyn MJ, Mewburn JD et al: Canine hindlimb blood flow and O₂ uptake after inhibition of EDNF/NO synthesis. *Journal of Applied Physiology*, 1994; 76: 1166-71
57. Ishibashi Y, Duncker DJ, Zhang J, Bache RJ: ATP-sensitive K⁺ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. *Circulation Research*, 1998; 82: 346-59
58. Bates TE, Loesch A, Burnstock G, Clark JB: Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? *Biochemical & Biophysical Research Communications*, 1996; 218: 40-4
59. Jourdain D, Mills L, Miles AM, Grisham MB: Effect of nitric oxide on hemoprotein-catalyzed oxidative reactions. *Nitric Oxide*, 1998; 2: 37-44
60. Kanner J, Harel S, Granit R: Nitric oxide as an antioxidant. *Archives of Biochemistry & Biophysics*, 1991; 289: 130-6
61. Hogg N, Kalyanaram B: Nitric oxide and lipid peroxidation. *Biochimica et Biophysica Acta*, 1999; 1411: 378-84
62. Arstall MA, Bailey C, Gross WL et al: Reversible S-nitrosylation of creatine kinase by nitric oxide in adult rat ventricular myocytes. *Journal of Molecular & Cellular Cardiology*, 1998; 30: 979-88
63. Kaasik A, Minajeva A, De Sousa E et al: Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase. *FEBS Letters*, 1999; 444: 75-7
64. Molina y Vedia L, McDonald B, Reep B et al: Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation [published erratum appears in *J Biol Chem* 1993 Feb 5; 268(4): 3016]. *Journal of Biological Chemistry*, 1992; 267: 24929-32
65. Mohr S, Hallak H, de Boitte A et al: Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. *Journal of Biological Chemistry*, 1999; 274: 9427-30
66. Mohr S, Stamler JS, Brune B: Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. *Journal of Biological Chemistry*, 1996; 271: 4209-14
67. Schuppe-Koistinen I, Moldeus P, Bergman T, Cotgreave IA: S-thiolation of human endothelial cell glyceraldehyde-3-phosphate dehydrogenase after hydrogen peroxide treatment. *European Journal of Biochemistry*, 1994; 221: 1033-7
68. Stefano GB, Prevot V, Cadet P, Dardik I: Vascular pulsations stimulating nitric oxide release during cyclic exercise may benefit health: a molecular approach (review). *International Journal of Molecular Medicine*, 2001; 7: 119-29